Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03880058 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of SLI-F06 in Wound Healing and Scar Appearance
A Phase 1 study, sponsored by Scarless Laboratories.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT03880058: Completed Phase 1 study, sponsored by Scarless Laboratories.
NCT03880058 is a Phase 1 study that has completed, run by Scarless Laboratories. The registered enrollment target is 22 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03880058, a Phase 1 study, has completed, sponsored by Scarless Laboratories.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
Multicenter, double-blind study comparing SLI-F06 to vehicle formulation buffer for the improvement in scar appearance and wound strength in routine surgical excisions, as well as post-operative abdominoplasty scar appearance.
Primary Outcome
POSAS is an established scale for assessing scar by both the patient and the observer. The overall opinion of the scar is reported on a scale of 1-10, with 1 being normal skin and 10 being the worst scar. Comparisons between treatment groups for efficacy analyses are based on 95% confidence intervals (CI) calculated using mixed models with treatment group as a fixed effect and subject as a random effect to account for multiple observations (i.e., scars) within subject.
Interventions
- DRUG SLI-F06
- DRUG Formulation buffer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2019-03-03 |
| Est. Completion | 2021-05-18 |
| Phase | Phase 1 |
What the finished NCT03880058 record still lists
NCT03880058 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 2 interventions - of which SLI-F06 is the first listed.
NCT03880058 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03880058 about?
NCT03880058 is a clinical study titled "Safety and Efficacy of SLI-F06 in Wound Healing and Scar Appearance". Multicenter, double-blind study comparing SLI-F06 to vehicle formulation buffer for the improvement in scar appearance and wound strength in routine surgical excisions, as well as post-operative abdominoplasty scar appearance.
What is the current status of trial NCT03880058?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2019-03-03. Estimated completion is 2021-05-18.
What interventions are being tested in trial NCT03880058?
The interventions under investigation include: SLI-F06 (DRUG), Formulation buffer (DRUG).
Who is sponsoring clinical trial NCT03880058?
This trial is sponsored by Scarless Laboratories, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03880058's enrollment target sits among peer trials
22 1601st of 2000 higher than 386 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI